Press releases
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
- Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces $180 Million Private Placement
More ▼
Key statistics
As of last trade Spyre Therapeutics Inc (3920:FRA) traded at 31.30, 8.12% above its 52-week low of 28.95, set on May 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 31.30 |
---|---|
High | 31.30 |
Low | 31.30 |
Bid | 31.25 |
Offer | 32.30 |
Previous close | 31.70 |
Average volume | 0.00 |
---|---|
Shares outstanding | 50.78m |
Free float | 35.73m |
P/E (TTM) | -- |
Market cap | 1.77bn USD |
EPS (TTM) | -71.35 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 07:01 BST.
More ▼